chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Initially, mild nausea, immediately (with 15 minutes of administration) . Resolved promptly within 30 minutes of injection.  Then, three hours after administration (at approx. 12.30 p.m.), the following symptoms in order of severity:  1. Severe tiredness/fatigue.  Lasted 4 hours.  Resolved when I took a half hour nap. 2. Sore throat.  Still present at 10.30 pm. 3. Swollen lymph nodes (lymphadenopathy).  Significant improvement after 4 hours from onset (3 hours after administration).  However, still present at 10.30 p.m. 4.  Feeling unwell/malaise.  Resolved after I took a nap. 5.  Dry eyes.  I had to remove my contact lenses and put on eyeglasses when I got home at approx. 2pm.   6.  Dry mouth.  Unresolved, even with drinking a lot of water and tea.  Symptoms were fairly severe.  I had to leave work and go home to rest.  I was unable to drive myself home.
Swelling, redness over upper arm/bicep, which spread to chest, itching, hot to touch. Patient was given Benadryl, 25 mg PO at time of incident report, and stated no relief.
Fatigue; Joint pain; Swollen lymph node on the right side of the face; This is a spontaneous report from a contactable consumer, the patient. A 70-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733), via an unspecified route of administration in the arm left on 30Mar2021 at 09:00 (at the age of 70-year-old), as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications were reported as many. The patient had received many medications (unspecified) within 2 weeks prior to the vaccination. The patient previously took first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208), via an unspecified route of administration in the arm left on 09Mar2021 at 09:00 (at the age of 70-year-old), as a single dose for COVID-19 immunisation. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 31Mar2021, the patient experienced fatigue, joint pain and a swollen lymph node on the right side of the face. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events fatigue, joint pain and swollen lymph node on the right side of the face was resolving.  No follow-up attempts are needed. No further information is expected.
Body aches; Fever; Chills; Joint pain; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Body aches), PYREXIA (Fever), CHILLS (Chills) and ARTHRALGIA (Joint pain) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 027L20A and 027L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 12-Mar-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced PAIN (Body aches). 12-Mar-2021, the patient experienced PYREXIA (Fever), CHILLS (Chills) and ARTHRALGIA (Joint pain). At the time of the report, PAIN (Body aches), PYREXIA (Fever), CHILLS (Chills) and ARTHRALGIA (Joint pain) outcome was unknown.            No relevant concomitant medication was reported. Treatment information was not provided   Reporter did not allow further contact
This is a spontaneous report from a contactable pharmacist via Pfizer sales representative. A 63-year-old male patient (father) received in Dec2018 a single dose of PREVNAR 13 for immunization. Medical history and concomitant medications were not reported. In the past, in Sep2014, the patient received PNEUMOVAX-23 for immunization. The patient was admitted to hospital recently (unspecified dates) for 5 days with pneumonia and then released. Additionally it was reported that patient had cough and lung congestion. Patient was still taking LEVAQUIN. Final outcome was unknown. Information on the batch number has been requested. Sender's Comments: Based on the information currently available, a lack of efficacy with pneumococcal 13-valent conjugate vaccine in this patient cannot be completely excluded.
Parents report that baby did not sleep well on night of vaccine administration.  He woke up the next morning and parents noticed an intermittent brief twitch of his right head and neck.  He did not appear to be in pain and was afebrile.  He continued to have same symptom into afternoon on 12/3 and again in morning only on 12/4 and 12/5.
The vaccination was administered on 02/12/2002 and pt was brought dead to the community hospital on 02/14/2002. Mother stated that she does not know what happened; infant had some fever. Mother woke up around noon, she found baby cold and stiff. She was not breathing. COD as per autopsy report: Bacterial Meningitis
Patient reports facial drooping with onset approximately 36 hours after vaccination with the first dosage of the Moderna COVID-19 vaccine.  Reports difficulty closing the left eye and drooping of the left corner of the mouth. Denies left eye pain and dryness. Denies hyperacusis. Denies fever. Physical examination shows left-sided flattening of the nasolabial fold and forehead. Bell's sign positive in the left eye. Reduced facial movements on the left side. Provisional diagnosis is Bell Palsy. Patient was prescribed prednisone taper and referred to neurology and PCP.
This spontaneous report as received from a pharmacist via a representative refers to a 62 year old female patient with no pertinent medical history and no drug reactions/allergies. On an unknown date the patient was vaccinated with a dose of ZOSTAVAX (lot # J013449, expiration date 24-JAN-2015) (dose and route unspecified). No concomitant medication was reported. On an unknown date the patient developed "localized injection site reactions, hives 3 inches in diameter, red and raised welts that were itchy and warm to touch , firm and painful". The outcome of "localized injection site reactions, hives 3 inches in diameter, red and raised welts that were itchy and warm to touch, firm and painful" was unknown. The patient sought medical attention via contact pharmacist. This is one of several reports received from same source. Additional information is not expected.
Client c/o dizziness, itchy throat, sweating and nausea. Client given water and snack and benadryl 12.5 mg po and monitored for 30 min. Blood pressure 120/79. After 25 min in post vac client stated he is feeling better. Client is up and walking, talking with partner in stable condition. Itchy throat is now relieved. Went over adverse reactions with client and when to seek medical attention.
Patient ended up with Arthritis in hands; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the parent. Other Case identifier(s): MOD-2022-461572 (Moderna).  A female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Arthritis in lower back and Neck only" (unspecified if ongoing), notes: Arthritis in lower back and Neck only. The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete but unknown manufacturer.), for Covid-19 immunization. The following information was reported: ARTHRITIS (non-serious), outcome "unknown", described as "Patient ended up with Arthritis in hands".  Additional information: She states, her daughter received Pfizer Covid-19 booster and she also ended up with arthritis in hands. Nurse suggested to take turmeric for arthritis in hands, but she did not take.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
After getting J & J vaccine she became light-headed, and hearing was distant. She then started sweating, lips were white and face was pale. She was helped to lie down on a mat with her feet up in a chair, with ice pack applied to back of neck and fan blowing in her direction. Blood pressure was taken, 110/72 and pulse was 92. After about 3 minutes she started feeling better. She continued to lay for about 5 more minutes. Then she was helped to sit up. No light-headedness remained and her color was starting to come back with being not so pale and lips were pink. At this time she was given some crackers and water to drink. She was called by a nurse the following day and said she did not have any other symptoms after leaving the vaccine site.
Pt. C/o numbness at the site for 1-2 days after the shot and recovered completely.
Flu like symptoms; Half dose; This spontaneous case was reported by a pharmacist and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu like symptoms) and INCORRECT DOSAGE ADMINISTERED (Half dose) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012F21A) for COVID-19 vaccination.     Concurrent medical conditions included Immunocompromised.   On 02-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .25 milliliter. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 02-Nov-2021, the patient experienced INFLUENZA LIKE ILLNESS (Flu like symptoms) and INCORRECT DOSAGE ADMINISTERED (Half dose). On 02-Nov-2021, INCORRECT DOSAGE ADMINISTERED (Half dose) had resolved. At the time of the report, INFLUENZA LIKE ILLNESS (Flu like symptoms) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication information was provided.   A immunocompromised patient received a booster dose of the Moderna COVID-19 vaccine (0.25 ml). Patient had flu like symptoms following receipt of the vaccine, but did not take any medications or treatments.
sx started 5-10 min later-shoulder pain started in L shoulder, vaccine location, went across to other shoulder. next day, walking to garage-could not breathe, chest pain, heartrate elevated, 104 fever. ED-chest xray, EKG, blood work. 3-4 hrs. waiting for heart rate to go down. sent her home 103 fever. felt bad for 4 days after that-heart rate, fever. no Rx. otc Tylenol for fever. Doctor told her she should not have had vaccine since she recently had Covid.
sick; flu like symptoms; Initial information regarding an unsolicited valid non-serious social media  case received from consumer or non-healthcare professional on 01-Dec-2020 .  This case involved female patient (age not reported) who got so sick (illness) and flu like symptoms (influenza like illness) when received INFLUENZA VACCINE.  The patient's medical history, past medical treatment, vaccination, concurrent condition, concomitant medication and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer, lot number not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date (unknown latency) after administration of INFLUENZA VACCINE, the patient got so sick (illness) that they had to give her 2 shots instead of 1 and had to give her smaller doses caused it mad her sick and flu like symptoms (influenza like illness).  Laboratory details were not reported.  It was not reported if the patient received a corrective treatment.  At the time of reporting, the outcome of event was unknown.  There will be no information available on the batch number for this case.
15 weeks and 3 days at time of first injection. Had a sore arm the next day. Baby was fine at midwife visit 2 days after shot.
Breakout of urticaria, unresolved by antihistamines and topical clobetasol.  Required injections of kenalog.
Pt. administered vaccine on 11/30/09; developed rash on top of both thighs on 11/20/09. Rash has continued thru 12/3/09. Pt taking over the counter BENADRYL and applying topical CORTISONE cream to areas.
Case number PHEH2014US016857 is an initial spontaneous report from a health care professional received on 21 Aug 2014 with a follow up information received from a physician on 22 Sep 2014. This report refers to an 11-year-old female patient. Past medical history was not reported. Her vaccination status was up to date. On 11 Aug 2014 at 9:44 am, she was vaccinated with an initial intramuscular dose of MENVEO (batch number: M13054) at a dose of 0.5 ml in the left deltoid and it was reported that she only received Men A lyophilized powder conjugate component reconstituted with a diluent and did not receive MenCYW-135 liquid component of the vaccine. No adverse event was reported following this administration error (wrong solution used in drug reconstitution). She was concomitantly administered BOOSTRIX (other manufacturer, batch number: 7KM4D) and GARDASIL (other manufacturer, batch number: J015378); both vaccines administered at a dose of 0.5 ml intramuscularly on 14 Aug 2014. No further information was provided. Follow up information received from a physician on 22 Sep 2014: Patient demographics (height and weight), vaccination status, vaccination site and concomitant vaccinations updated.
tested slightly postive for Hepatitis B antigen /p receiving Engerix B vax
This spontaneous report was received from Registered Nurse regarding to a 12 month old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On 13-JUN-2016, the patient was vaccinated with improperly stored VARIVAX (lot # L004649, expiry date 11-FEB-2017) (therapy type digital data logger) dosage regimen unknown. It was reported that the vaccine was exposed to a temperature excursion of 23 degree Celsius for a time frame of 1 hour and 29 minutes and the temperature was back in range. It was reported that the vaccine was not subjected to previous temperature excursion. Product quality complaint (PQC) was not filed. This is one of the several reports received form the same reporter. Additional information had been requested.
I felt the usual symptoms of fatigue, body aches, chills after my first and second dose. However,  this symptom was not well known in December/January.  I started experiencing waves of heartburn and irregular heart beats.  I ended up checking my blood pressure on my boyfriend monitor and it was 144/90 late January.  I do wear a fitbit and my resting heart rate was around 72 to 76bpm. Resting....My blood pressure on healthcare check ups (one in March and one in July) were also high in that range. I am a young healthy individual, so I never though about going to the doctors. Waves of on and off heart palpitations lasted till August (about 6 months after the vaccine).  I had never experienced heart palpitations before this. There was one night I thought I was going to have a myocardial infarction and took a few doses of aspirin.  In the spring when others were getting the vaccine, I noted the reporting of younger adults experiencing myocarditis and I wonder if that happened to me.  I enjoy my field of work as a healthcare professional at a nursing home, but I am afraid of my heart health if there were to be a mandate for a booster...so that is why I am now voicing my symptoms.
PATIENT COMPLAINED OF DIZZINESS AND ALSO STATED THAT HE FEELS LIKE HE WANTS TO FAINT. ASSESSED DONE  AND PATIENT SENT HOME IN STABLE CONDITION.
Information has been received from a registered pharmacist concerning a 20 year old male with no known drug allergies who in 1995 was vaccinated with a two dose series of hep A virus vaccine inactivated. In 1998 the pt developed hepatitis A. Unspecified medical attention was sought. Follow up information was received on 4/17/03 from a pharmacist indicating that the patient was treated for hepatitis A bt she did not know how he was treated. It was noted that the patient had recovered. No additional information was available. Upon internal review, hep A was considered to be an other important medical event (OMIC). Additional info has been requested.
COULD NOT EAT; GASSY STOMACH; Headache; Sore arm; FELT TIRED; This spontaneous case was reported by a consumer and describes the occurrence of HYPOPHAGIA (COULD NOT EAT), FLATULENCE (GASSY STOMACH), HEADACHE (Headache), PAIN IN EXTREMITY (Sore arm) and FATIGUE (FELT TIRED) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 025821A and 026B21A) for COVID-19 vaccination.    Co-suspect product included non-company product PANCREATIN (CREON) capsule for an unknown indication.    The patient's past medical history included Whipple's operation in 2020. Concurrent medical conditions included Cancer (rare type of unrecalled cancer), Drug allergy (OXYCODONE ALLERGY MANIFESTED BY HALLLUCINATION), Drug allergy (SPIRIVA HANDIHALER ALLERGY MANIFESTED BY ANXIETY, BREATHING PROBLEM), Non-tobacco user and Abstains from alcohol. Concomitant products included LISINOPRIL, PANTOPRAZOLE, SENNA ALEXANDRINA, METOPROLOL SUCCINATE, INSULIN LISPRO (HUMALOG) and INSULIN GLARGINE (LANTUS) for an unknown indication.   On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started PANCREATIN (CREON) (Oral) at an unspecified dose three times a day. On an unknown date, PANCREATIN (CREON) (Oral) dosage was changed to at an unspecified dose three times a day, PANCREATIN (CREON) (Oral) dosage was changed to at an unspecified dose three times a day and PANCREATIN (CREON) (Oral) dosage was changed to at an unspecified dose three times a day. On 01-Apr-2021, the patient experienced HEADACHE (Headache), PAIN IN EXTREMITY (Sore arm) and FATIGUE (FELT TIRED). On 15-Dec-2021, the patient experienced HYPOPHAGIA (COULD NOT EAT) and FLATULENCE (GASSY STOMACH). On 02-Apr-2021, HEADACHE (Headache) and PAIN IN EXTREMITY (Sore arm) had resolved. On 03-Apr-2021, FATIGUE (FELT TIRED) had resolved. At the time of the report, HYPOPHAGIA (COULD NOT EAT) and FLATULENCE (GASSY STOMACH) had not resolved.            On 01-Apr-2021, the patient experienced headache, sore arm and felt tired. On 15-Dec-2021, the patient could not eat, patient tapered down Creon to 2 capsules per meal and one capsule per snack when nearly ran out of Creon and had a gassy stomach. No treatment information was provided. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   This case was linked to MOD-2022-623005 (Patient Link).   Reporter did not allow further contact
Information has been received from a health professional concerning an adult pt who less than 2 days ago on approx 16Oct05 was vaccinated IM with a 0.5ml dose of pneumococcal 23v polysaccharide vaccine. (lot 649914/0578P). In Oct 2005 the pt experienced an injection site reaction including redness, swelling and local pain at the site. The pt was treated with diphenhydramine hcl (Benadryl). At the time of this report, the pt was still recovering. It was also noted that this was a revaccination and the pt had at least one and possibly as many as 6 prior vaccinations before this dose. No product quality complaint was involved. Injection site redness, injection site swelling and injection site pain were considered to be immediately life threatening, other important medical events (OMIC) and disabling by the reporter. Additional information has been requested.
ED to Hosp-Admission Discharged   9/19/2021 - 9/21/2021 (2 days)  Last attending ? Treatment team COVID-19  Presenting Problem/History of Present Illness/Reason for Admission Hypoxia [R09.02] Pulmonary embolism associated with COVID-19 (CMS/HCC) [U07.1, I26.99] COVID-19 [U07.1] Chronic combined diastolic and systolic heart failure     Hospital Course   77-year-old male admitted to the hospital with findings of acute pulmonary embolism in the setting of COVID-19 without significant pneumonia.  Was found to have respiratory insufficiency with hypoxia acute present on admission.  Was started on heparin infusion as well as remdesivir, monitored overnight with some improvement.  This morning upon evaluating him he appeared stable for discharge home.  He was taken off of heparin, converted to Eliquis which she will continue for 3 months.  We will stop acute interventions for COVID-19 given that he does not show signs of viral pneumonia.  Hypoxia is likely related to VTE.  He was instructed to isolate until October 3.  He will follow-up with PCP within 7 to 10 days.  Supplemental oxygen was provided at discharge as patient did qualify.  If there are complications regarding cost and affordability of Eliquis it would be recommended that patient's physician bridge him with Eliquis to Coumadin over the next month.  I stopped his Plavix, he should not be on triple therapy at this time, he will be on Eliquis, and aspirin and after 3 months if taken off of Eliquis could be then put back on Plavix. ED to Hosp-Admission Current   10/1/2021 - present (3 days)hospital    Last attending ? Treatment team Ventricular tachycardia (CMS/HCC)  Chief Complaint Patient presents with ? Irregular Heart Beat     1. Ischemic cardiomyopathy status post BiV ICD, now with recurrent V. tach.  Admit to general medical floor.  Monitor on telemetry.  Patient to be admitted for initiation of sotalol therapy, cardiology to follow.  Monitor QTC per protocol.  Check TSH.   2. Elevated troponins.  Likely due to demand ischemia in the setting of V. tach.  Trend troponins to peak, check 2D echocardiogram.  2D echocardiogram from September 7, 2021 shows reduced EF 40 to 45%, grade 2 diastolic dysfunction.  Await cardiology recommendations. 3. Subacute PE.  Patient on Eliquis therapy, continue for now. Check D-dimer to evaluate for worsening PE, given that he is now having recurrent V. tach episodes. 4. Type 2 diabetes.  Hold oral hypoglycemics.  Will place on insulin sliding scale Accu-Cheks per protocol. 5. CAD status post PCI.  Continue aspirin, statin, beta-blocker 6. COVID-19 infection.  Patient is tolerating room air, monitor clinically.  Continue supportive care with as needed albuterol inhaler, Mucinex.